Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small hairpin RNA

被引:31
作者
Li, MJ
McMahon, R
Snyder, DS
Yee, JK
Rossi, JJ
机构
[1] City Hope Natl Med Ctr, Div Mol Biol, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Div Hematol Bone Marrow Transplantat, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Dept Virol, Duarte, CA 91010 USA
[4] Beckman Res Inst, Duarte, CA 91010 USA
关键词
D O I
10.1089/154545703322617087
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic myeloid leukemia (CML) is characterized by a reciprocal chromosomal translocation between chromosomes 9 and 22 t(9;22)(q34;q11) that causes fusion of the bcr and abl genes. Transcription and splicing of the fusion gene generate two major splice variants of the bcr/abl transcript that encode an oncoprotein with tyrosine kinase activity. We have taken advantage of lentiviral vector-mediated delivery of anti-bcr/abl short hairpin RNAs (shRNA) to downregulate the bcr/abl transcript in Philadelphia chromosome-positive (Ph+) K562 leukemia cells. This downregulation caused complete inhibition of proliferation of these cells and was accompanied by >90% inhibition of the bcr/abl transcript and p210 protein. These results demonstrate the feasibility of using a lentiviral vector to stably transduce therapeutic shRNAs into leukemia cells for the potential ex vivo purging of Ph+ cells in an autologous hematopoietic cell transplant setting. Furthermore, the robust expression of the shRNAs from our lentiviral vector suggests that this system could be generally useful for the expression of other shRNAs.
引用
收藏
页码:401 / 409
页数:9
相关论文
共 62 条
[21]   ACUTE-LEUKEMIA IN BCR/ABL TRANSGENIC MICE [J].
HEISTERKAMP, N ;
JENSTER, G ;
TENHOEVE, J ;
ZOVICH, D ;
PATTENGALE, PK ;
GROFFEN, J .
NATURE, 1990, 344 (6263) :251-253
[22]   LOCALIZATION OF THE C-ABL ONCOGENE ADJACENT TO A TRANSLOCATION BREAK POINT IN CHRONIC MYELOCYTIC-LEUKEMIA [J].
HEISTERKAMP, N ;
STEPHENSON, JR ;
GROFFEN, J ;
HANSEN, PF ;
DEKLEIN, A ;
BARTRAM, CR ;
GROSVELD, G .
NATURE, 1983, 306 (5940) :239-242
[23]   Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy [J].
Hochhaus, A ;
Kreil, S ;
Corbin, AS ;
La Rosée, P ;
Müller, MC ;
Lahaye, T ;
Hanfstein, B ;
Schoch, C ;
Cross, N ;
Berger, U ;
Gschaidmeier, H ;
Druker, BJ ;
Hehlmann, R .
LEUKEMIA, 2002, 16 (11) :2190-2196
[24]   TREATMENT OF PHILADELPHIA-CHROMOSOME-POSITIVE HUMAN LEUKEMIA IN SCID MOUSE MODEL WITH HERBIMYCIN-A, BCR-ABL TYROSINE KINASE-ACTIVITY INHIBITOR [J].
HONMA, Y ;
MATSUO, Y ;
HAYASHI, Y ;
OMURA, S .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (05) :685-688
[25]   Modulation of HIV-1 replication by RNA interference [J].
Jacque, JM ;
Triques, K ;
Stevenson, M .
NATURE, 2002, 418 (6896) :435-438
[26]  
James H, 1996, LEUKEMIA, V10, P1054
[27]   Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias [J].
Kantarjian, HM ;
Talpaz, M .
SEMINARS IN ONCOLOGY, 2001, 28 (05) :9-18
[28]   Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells [J].
Lee, NS ;
Dohjima, T ;
Bauer, G ;
Li, HT ;
Li, MJ ;
Ehsani, A ;
Salvaterra, P ;
Rossi, J .
NATURE BIOTECHNOLOGY, 2002, 20 (05) :500-505
[29]   Inhibition of HIV-1 infection by lentiviral vectors expressing pol III-promoted anti-HIV RNAs [J].
Li, MJ ;
Bauer, G ;
Michienzi, A ;
Yee, JK ;
Lee, NS ;
Kim, J ;
Li, S ;
Castanotto, D ;
Zaia, J ;
Rossi, JJ .
MOLECULAR THERAPY, 2003, 8 (02) :196-206
[30]   TYROSINE KINASE-ACTIVITY AND TRANSFORMATION POTENCY OF BCR-ABL ONCOGENE PRODUCTS [J].
LUGO, TG ;
PENDERGAST, AM ;
MULLER, AJ ;
WITTE, ON .
SCIENCE, 1990, 247 (4946) :1079-1082